{
    "info": {
        "nct_id": "NCT04579679",
        "official_title": "An Open-Label Phase 2 Study of Surufatinib in Patients with Neuroendocrine Tumours in Europe",
        "inclusion_criteria": "1. Has histologically or cytologically documented, locally advanced, or metastatic NET and has progressed on at least 1 prior line of therapy, but no more than 3 therapies;\n2. Has radiologic evidence of progressive tumour within 12 months of study enrolment\n3. Is willing and able to provide informed consent\n4. Is ≥18 years of age\n5. Has measurable lesions according to RECIST Version 1.1\n6. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n7. Female patients of childbearing potential and male patients with partners of childbearing potential agree to use a highly effective form(s) of contraception\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Has an AE due to previous anti-tumour therapy that has not recovered to ≤CTCAE Grade 1, except alopecia and peripheral neurotoxicity with ≤CTCAE Grade 2 caused by platinum chemotherapy\n2. Major surgery within previous 4 weeks or radiation therapy within 2 weeks prior to the start of treatment.\n3. Prior VEGF/VEGFR-targeted therapy\n4. Uncontrollable hypertension, defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg, despite antihypertensive medication\n5. Gastrointestinal disease or condition within 6 months prior to first dose\n6. Has a history or presence of a serious haemorrhage (>30 mL within 3 months) or haemoptysis (>5 mL blood within 4 weeks) within 6 months of first dose of study drug.\n7. Clinically significant cardiovascular disease.\n8. Brain metastases and/or spinal cord compression untreated with surgery and/or radiotherapy, and without clinical imaging evidence of stable disease (SD) for 14 days or longer; patients requiring steroids within 4 weeks prior to start of study treatment will be excluded.\n9. A high risk of bleeding at screening due to tumour invasion into major vessels, such as pulmonary artery, the superior vena cava, or the inferior vena cava, as determined by investigators.\n10. Has arterial thrombosis or deep venous thrombosis within 6 months prior to first dosing, or thromboembolic events (including stroke and/or transient ischaemic attack) within 12 months.\n11. Has a clinically meaningful ongoing infection (eg, requiring intravenous treatment with anti-infective therapy)",
        "miscellaneous_criteria": "Key"
    },
    "inclusion_lines": [
        {
            "line": "3. Is willing and able to provide informed consent",
            "criterions": [
                {
                    "exact_snippets": "Is willing and able to provide informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key eligibility criteria",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "N/A"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Has measurable lesions according to RECIST Version 1.1",
            "criterions": [
                {
                    "exact_snippets": "Has measurable lesions according to RECIST Version 1.1",
                    "criterion": "measurable lesions",
                    "requirements": [
                        {
                            "requirement_type": "measurability (RECIST 1.1)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Female patients of childbearing potential and male patients with partners of childbearing potential agree to use a highly effective form(s) of contraception",
            "criterions": [
                {
                    "exact_snippets": "Female patients of childbearing potential",
                    "criterion": "female patient childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "male patients with partners of childbearing potential",
                    "criterion": "male patient with partner of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "partner childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agree to use a highly effective form(s) of contraception",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use highly effective contraception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Has radiologic evidence of progressive tumour within 12 months of study enrolment",
            "criterions": [
                {
                    "exact_snippets": "radiologic evidence of progressive tumour within 12 months of study enrolment",
                    "criterion": "progressive tumour",
                    "requirements": [
                        {
                            "requirement_type": "evidence type",
                            "expected_value": "radiologic"
                        },
                        {
                            "requirement_type": "progression timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "progression status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Is ≥18 years of age",
            "criterions": [
                {
                    "exact_snippets": "Is ≥18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Has histologically or cytologically documented, locally advanced, or metastatic NET and has progressed on at least 1 prior line of therapy, but no more than 3 therapies;",
            "criterions": [
                {
                    "exact_snippets": "Has histologically or cytologically documented, locally advanced, or metastatic NET",
                    "criterion": "neuroendocrine tumor (NET)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically documented",
                                "cytologically documented"
                            ]
                        },
                        {
                            "requirement_type": "disease stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "has progressed on at least 1 prior line of therapy, but no more than 3 therapies",
                    "criterion": "prior lines of therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior therapies",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "lines"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "lines"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "3. Prior VEGF/VEGFR-targeted therapy",
            "criterions": [
                {
                    "exact_snippets": "Prior VEGF/VEGFR-targeted therapy",
                    "criterion": "prior VEGF/VEGFR-targeted therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Has arterial thrombosis or deep venous thrombosis within 6 months prior to first dosing, or thromboembolic events (including stroke and/or transient ischaemic attack) within 12 months.",
            "criterions": [
                {
                    "exact_snippets": "Has arterial thrombosis ... within 6 months prior to first dosing",
                    "criterion": "arterial thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to first dosing"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Has ... deep venous thrombosis within 6 months prior to first dosing",
                    "criterion": "deep venous thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to first dosing"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "thromboembolic events (including stroke and/or transient ischaemic attack) within 12 months",
                    "criterion": "thromboembolic events (including stroke and/or transient ischaemic attack)",
                    "requirements": [
                        {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Clinically significant cardiovascular disease.",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant cardiovascular disease",
                    "criterion": "cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Major surgery within previous 4 weeks or radiation therapy within 2 weeks prior to the start of treatment.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within previous 4 weeks",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "radiation therapy within 2 weeks prior to the start of treatment",
                    "criterion": "radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. A high risk of bleeding at screening due to tumour invasion into major vessels, such as pulmonary artery, the superior vena cava, or the inferior vena cava, as determined by investigators.",
            "criterions": [
                {
                    "exact_snippets": "A high risk of bleeding at screening due to tumour invasion into major vessels, such as pulmonary artery, the superior vena cava, or the inferior vena cava, as determined by investigators.",
                    "criterion": "risk of bleeding at screening",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "high"
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "tumour invasion into major vessels (pulmonary artery, superior vena cava, inferior vena cava)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Brain metastases and/or spinal cord compression untreated with surgery and/or radiotherapy, and without clinical imaging evidence of stable disease (SD) for 14 days or longer; patients requiring steroids within 4 weeks prior to start of study treatment will be excluded.",
            "criterions": [
                {
                    "exact_snippets": "Brain metastases and/or spinal cord compression untreated with surgery and/or radiotherapy",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated with surgery and/or radiotherapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "Brain metastases and/or spinal cord compression untreated with surgery and/or radiotherapy",
                    "criterion": "spinal cord compression",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated with surgery and/or radiotherapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "without clinical imaging evidence of stable disease (SD) for 14 days or longer",
                    "criterion": "stable disease (SD) on clinical imaging",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 14,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients requiring steroids within 4 weeks prior to start of study treatment will be excluded",
                    "criterion": "steroid requirement",
                    "requirements": [
                        {
                            "requirement_type": "use within prior period",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Has an AE due to previous anti-tumour therapy that has not recovered to ≤CTCAE Grade 1, except alopecia and peripheral neurotoxicity with ≤CTCAE Grade 2 caused by platinum chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "Has an AE due to previous anti-tumour therapy that has not recovered to ≤CTCAE Grade 1",
                    "criterion": "adverse event due to previous anti-tumour therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "CTCAE Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except alopecia and peripheral neurotoxicity with ≤CTCAE Grade 2 caused by platinum chemotherapy",
                    "criterion": "alopecia caused by platinum chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "CTCAE Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except alopecia and peripheral neurotoxicity with ≤CTCAE Grade 2 caused by platinum chemotherapy",
                    "criterion": "peripheral neurotoxicity caused by platinum chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "CTCAE Grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Has a clinically meaningful ongoing infection (eg, requiring intravenous treatment with anti-infective therapy)",
            "criterions": [
                {
                    "exact_snippets": "clinically meaningful ongoing infection",
                    "criterion": "ongoing infection",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring intravenous treatment with anti-infective therapy",
                    "criterion": "ongoing infection",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "intravenous anti-infective therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Has a history or presence of a serious haemorrhage (>30 mL within 3 months) or haemoptysis (>5 mL blood within 4 weeks) within 6 months of first dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "history or presence of a serious haemorrhage (>30 mL within 3 months) ... within 6 months of first dose of study drug",
                    "criterion": "serious haemorrhage",
                    "requirements": [
                        {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "volume",
                            "expected_value": {
                                "operator": ">",
                                "value": 30,
                                "unit": "mL"
                            }
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "relative to first dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "history or presence of ... haemoptysis (>5 mL blood within 4 weeks) within 6 months of first dose of study drug",
                    "criterion": "haemoptysis",
                    "requirements": [
                        {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "volume",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "mL"
                            }
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "relative to first dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Gastrointestinal disease or condition within 6 months prior to first dose",
            "criterions": [
                {
                    "exact_snippets": "Gastrointestinal disease or condition within 6 months prior to first dose",
                    "criterion": "gastrointestinal disease or condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to first dose"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Uncontrollable hypertension, defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg, despite antihypertensive medication",
            "criterions": [
                {
                    "exact_snippets": "Uncontrollable hypertension, defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg, despite antihypertensive medication",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "controllability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "systolic blood pressure ≥140 mmHg",
                    "criterion": "systolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 140,
                                "unit": "mmHg"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "diastolic blood pressure ≥90 mmHg",
                    "criterion": "diastolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 90,
                                "unit": "mmHg"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "despite antihypertensive medication",
                    "criterion": "antihypertensive medication",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "key"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}